Burney Co. Acquires New Shares in Omnicell, Inc. $OMCL

Burney Co. purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 213,242 shares of the company’s stock, valued at approximately $7,118,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. bought a new position in shares of Omnicell during the 2nd quarter valued at $26,000. Clearstead Advisors LLC lifted its holdings in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Omnicell during the 4th quarter valued at $58,000. Parkside Financial Bank & Trust lifted its position in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares in the last quarter. Finally, First Horizon Corp boosted its stake in Omnicell by 54.6% in the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after purchasing an additional 564 shares during the period. Institutional investors own 97.70% of the company’s stock.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on OMCL shares. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Craig Hallum restated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research report on Wednesday, April 29th. Wells Fargo & Company boosted their target price on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. UBS Group set a $60.00 target price on shares of Omnicell and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Zacks Research upgraded Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $59.86.

Omnicell Stock Performance

Shares of Omnicell stock opened at $45.24 on Tuesday. The company has a market capitalization of $2.06 billion, a PE ratio of 102.82, a P/E/G ratio of 1.11 and a beta of 0.96. The company has a 50-day simple moving average of $41.92 and a two-hundred day simple moving average of $41.52. Omnicell, Inc. has a one year low of $26.84 and a one year high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same period last year, the business earned $0.26 EPS. The company’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts expect that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.